NCT04569747: An ongoing trial by Dana-Farber Cancer Institute
This trial is ongoing. It must report results 2 years from now.
Full data
Full entry on ClinicalTrials.gov | NCT04569747 |
---|---|
Title | 20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT) |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Jan. 11, 2021 |
Completion date | Sept. 1, 2026 |
Required reporting date | Sept. 1, 2027, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
Days late | None |